Literature DB >> 1488627

Macrolides and the immune system.

P J McDonald1, H Pruul.   

Abstract

Macrolides achieve much greater in vivo and clinical efficacy than might be expected from standard in vitro testing. There is accumulating evidence to suggest that macrolides act synergistically with the host immune system. In contrast to beta-lactams, macrolides have increased activity in serum. Phagocytes are a key component of the host immune system against intracellular pathogens. Antibiotics can alter bacterial susceptibility to both uptake and intracellular phagocytic killing. Macrolides appear to enhance phagocyte killing of bacteria whereas beta-lactams have a limited or negative effect. Both macrolides and quinolones achieve high intraphagocytic concentrations that are associated with intracellular antibacterial activity. Azithromycin, which is chemically related to the macrolides, achieves particularly high intracellular levels within phagocytes which may be associated with enhanced synergistic activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1488627

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  6 in total

1.  Tailoring Antibiotic Treatment to Host Immune Status: The Host, Not the Drug, Determines Outcome.

Authors:  Peter J. McDonald; Hendrik Pruul
Journal:  Curr Infect Dis Rep       Date:  2001-08       Impact factor: 3.725

2.  Synergistic effect of azithromycin on the phagocytic killing of Staphylococcus aureus by human polymorphonuclear leukocytes.

Authors:  I Herrera-Insúa; P Pérez; C Ramos; P Martínez; M L Gómez-Lus; J Prieto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 3.  The immune response and antibacterial therapy.

Authors:  Olachi Anuforom; Graham R Wallace; Laura V Piddock
Journal:  Med Microbiol Immunol       Date:  2014-09-05       Impact factor: 3.402

Review 4.  Intracellular concentrations of antibacterial agents and related clinical implications.

Authors:  J D Butts
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

5.  Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens.

Authors:  I Odenholt-Tornqvist; E Löwdin; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

6.  Azithromycin or erythromycin? Macrolides for non-cystic fibrosis bronchiectasis in adults: A systematic review and adjusted indirect treatment comparison.

Authors:  Wen Li; Zhong Qin; Jie Gao; Zhibin Jiang; Yihui Chai; Liancheng Guan; Yunzhi Chen
Journal:  Chron Respir Dis       Date:  2018-08-12       Impact factor: 2.444

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.